Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06969287 · ClinicalTrials.gov registry record · Phase 3

Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery

A Phase 3 study of Delirium and Surgery--Complications, sponsored by Washington University School of Medicine.

Recruiting
Registry status
Phase 3
Development phase
46
Enrollment target
1
Study location

NCT06969287: Recruiting Phase 3 study of Delirium and Surgery--Complications, sponsored by Washington University School of Medicine.

NCT06969287 is a Phase 3 study of Delirium and Surgery--Complications that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 46 participants, below the 887-participant average among 62 other Delirium trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06969287, a Phase 3 study of Delirium and Surgery--Complications, is actively recruiting participants, sponsored by Washington University School of Medicine.

RECRUITING
Registry status
Phase 3
Development phase
46 participants
Enrollment target
1
Study location

Study Summary

The investigation will establish biological plausibility and infrastructure required for a multisite clinical trial evaluating the re-purposing of fluvoxamine to mitigate postoperative delirium risk in geriatric patients undergoing non-cardiac non-intracranial surgery.

Primary Outcome

Feasibility assessed as number of eligible participants enrolled per month by an audit of the study screening and recruitment logs.

Interventions

  • DRUG Placebo
  • DRUG Fluvoxamine

Study Locations (1)

Missouri

  • Washington University School of Medicine/Barnes-Jewish Hospital - St Louis

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2026-03-07
Est. Completion 2028-04-01
Phase Phase 3

What NCT06969287 shows while recruiting

NCT06969287 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 887-participant average among 62 other Delirium trials with a reported enrollment target (95% lower).

The record links to 2 conditions, with Delirium appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06969287 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT06969287 about?

NCT06969287 is a clinical study titled "Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery". The investigation will establish biological plausibility and infrastructure required for a multisite clinical trial evaluating the re-purposing of fluvoxamine to mitigate postoperative delirium risk in geriatric patients undergoing non-cardiac non-intracranial surgery.

What is the current status of trial NCT06969287?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 46 participants. The study started on 2026-03-07. Estimated completion is 2028-04-01.

What conditions does trial NCT06969287 study?

This clinical trial studies the following conditions: Delirium, Surgery--Complications.

What interventions are being tested in trial NCT06969287?

The interventions under investigation include: Placebo (DRUG), Fluvoxamine (DRUG).

Who is sponsoring clinical trial NCT06969287?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06969287 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Delirium

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06969287's enrollment target sits among peer trials

46 52nd of 62 higher than 11 of 62 other Delirium trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Delirium trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01890590 · 46 participants · NA

    A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • NCT03191149 · 46 participants · Phase 2

    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • NCT03510208 · 46 participants · Phase 1

    Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

  • NCT04048278 · 46 participants · Early Phase 1

    Lidocaine Infusion in Pancreatic Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06969287, the US trial registry maintained by the National Library of Medicine. NCT06969287 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.